RNA therapeutics are currently enjoying the center stage spotlight in the drug development sector, thanks to the quick turnaround time of COVID-19 vaccines. Scientists have steadily worked on improving the stability, durability and delivery of mRNA and siRNA for decades and RNA therapeutics are primed to be at the frontline of biologics to treat cancer, infectious diseases and rare genetic disorders. At the 25th annual meeting of the American Society for Gene and Cell Therapy (ASGCT), researchers from industry and academia shared their experience of developing RNA drugs for various applications and improving their efficacy, targeting and specificity.